Literature DB >> 3886209

The effect of vasopressin infusion on glucose metabolism in man.

B A Spruce, A J McCulloch, J Burd, H Orskov, A Heaton, P H Baylis, K G Alberti.   

Abstract

Studies on intact animals and isolated rat hepatocytes have shown that arginine vasopression (AVP) stimulates glycogen phosphorylase to break down glycogen and raise plasma glucose concentrations. Since no similar work has been performed on healthy human adults, the effect of moderate (25 pmol/min) and high (75 pmol/min) dose AVP infusion on plasma glucose, intermediary metabolites, glucose kinetics, and circulating glucagon and insulin concentrations was investigated. After AVP infusion, plasma glucose rose from 4.9 +/- 0.1 to a peak of 5.7 +/- 0.2 mmol/l (P less than 0.001), but no changes in blood lactate, pyruvate, alanine, glycerol or 3-hydroxybutyrate concentrations were observed. The glucose rise was accounted for entirely by an increase in the rate of appearance of glucose from 11.19 +/- 0.43 to 13.38 +/- 0.63 mu mol/kg/min (P less than 0.001). Infusion of AVP also increased plasma glucagon concentrations from 38 +/- 8 to 79 +/- 20 pg/l (P less than 0.01). The hyperglycaemic effect of AVP may be mediated solely by stimulation of glucagon release, but we cannot exclude direct stimulation of glycogen phosphorylase activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3886209     DOI: 10.1111/j.1365-2265.1985.tb00145.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  31 in total

1.  Insulin hypersensitivity in mice lacking the V1b vasopressin receptor.

Authors:  Yoko Fujiwara; Masami Hiroyama; Atsushi Sanbe; Toshinori Aoyagi; Jun-Ichi Birumachi; Junji Yamauchi; Gozoh Tsujimoto; Akito Tanoue
Journal:  J Physiol       Date:  2007-08-02       Impact factor: 5.182

Review 2.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

3.  Vasopressin and diabetic ketoacidosis.

Authors:  P J Grant; P G Wiles; J A Davies; C R Prentice
Journal:  Diabetologia       Date:  1986-06       Impact factor: 10.122

4.  AVP neurons in the paraventricular nucleus of the hypothalamus regulate feeding.

Authors:  Hongjuan Pei; Amy K Sutton; Korri H Burnett; Patrick M Fuller; David P Olson
Journal:  Mol Metab       Date:  2014-01-08       Impact factor: 7.422

5.  Plasma copeptin and the risk of diabetes mellitus.

Authors:  Sofia Enhörning; Thomas J Wang; Peter M Nilsson; Peter Almgren; Bo Hedblad; Göran Berglund; Joachim Struck; Nils G Morgenthaler; Andreas Bergmann; Eero Lindholm; Leif Groop; Valeria Lyssenko; Marju Orho-Melander; Christopher Newton-Cheh; Olle Melander
Journal:  Circulation       Date:  2010-05-03       Impact factor: 29.690

6.  Metabolic and Kidney Diseases in the Setting of Climate Change, Water Shortage, and Survival Factors.

Authors:  Richard J Johnson; Peter Stenvinkel; Thomas Jensen; Miguel A Lanaspa; Carlos Roncal; Zhilin Song; Lise Bankir; Laura G Sánchez-Lozada
Journal:  J Am Soc Nephrol       Date:  2016-06-09       Impact factor: 10.121

7.  Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats.

Authors:  Christopher Taveau; Catherine Chollet; Ludovic Waeckel; Dorinne Desposito; Daniel G Bichet; Marie-Françoise Arthus; Christophe Magnan; Erwann Philippe; Valerie Paradis; Fabienne Foufelle; Isabelle Hainault; Sofia Enhorning; Gilberto Velho; Ronan Roussel; Lise Bankir; Olle Melander; Nadine Bouby
Journal:  Diabetologia       Date:  2015-01-27       Impact factor: 10.122

8.  Hyperammonaemia in V1a vasopressin receptor knockout mice caused by the promoted proteolysis and reduced intrahepatic blood volume.

Authors:  Masami Hiroyama; Toshinori Aoyagi; Yoko Fujiwara; Sayuri Oshikawa; Atsushi Sanbe; Fumio Endo; Akito Tanoue
Journal:  J Physiol       Date:  2007-03-22       Impact factor: 5.182

9.  Relationship between non-osmotic arginine vasopressin secretion and hemoglobin A1c levels in adult patients with congenital heart disease.

Authors:  Tomoaki Murakami; Yoko Horibata; Shigeru Tateno; Yasutaka Kawasoe; Koichiro Niwa
Journal:  Heart Vessels       Date:  2018-11-20       Impact factor: 2.037

10.  Increase by naloxone of arginine vasopressin and oxytocin responses to insulin-induced hypoglycemia in obese men.

Authors:  V Coiro; L Capretti; G Speroni; A Castelli; L Bianconi; U Cavazzini; A Marcato; R Volpi; P Chiodera
Journal:  J Endocrinol Invest       Date:  1990-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.